PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Travanti Pharma Inc.	06/07/2011

RECEIVING PARTY DATA

Name:	Teikoku Pharma USA, Inc.	
Street Address:	1718 Ringwood Avenue	
City:	San Jose	
State/Country:	CALIFORNIA	
Postal Code:	95131	

PROPERTY NUMBERS Total: 7

Property Type	Number
Application Number:	10763628
Application Number:	12412144
Application Number:	12621619
Application Number:	12952516
Application Number:	12976610
PCT Number:	US0502246
PCT Number:	US1000552

CORRESPONDENCE DATA

Fax Number: (650)327-3231

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 650-327-3400

Email: millsaps@bozpat.com

Correspondent Name: Bozicevic, Field & Francis LLP

Address Line 1: 1900 University Avenue

Address Line 2: Suite 200

Address Line 4: East Palo Alto, CALIFORNIA 94303

PATENT

REEL: 026435 FRAME: 0494

501563473

ATTORNEY DOCKET NUMBER:	TEIK-036*
NAME OF SUBMITTER:	Bret E. Field
Total Attachments: 2 source=TEIK-036-ASG#page1.tif source=TEIK-036-ASG#page2.tif	

PATENT REEL: 026435 FRAME: 0495

ASSIGNMENT OF APPLICATION

Atty Docket No. TEIK-036

THIS ASSIGNMENT, by Travanti Pharma Inc. (hereinafter referred to as the Assignor), having its principal place of business at 2520 Pilot Knob Road, Suite 100, Mendota Heights, Minnesota 55120, witnesseth:

WHEREAS, the said Assignor has acquired right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, the inventions entitled:

"ABUSE POTENTIAL REDUCTION IN ABUSABLE SUBSTANCE DOSAGE FORM" and

"MEDICATION DISPOSAL SYSTEM"

as well as to any and all improvements thereof, Letters Patent and applications for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon, including the specific Patent and Patent applications listed in Appendix A to this Assignment;

WHEREAS, Teikoku Pharma USA, Inc., a corporation duly organized under and pursuant to the laws of California and having their principal place of business at 1718 Ringwood Avenue, San Jose, California 95131-1711 (hereinafter referred to as the Assignee) is desirous of acquiring all of Assignor's right, title and interest in and to said inventions and said Letters Patent and applications for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW THEREFORE, for good and sufficient considerations, the receipt of which is hereby acknowledged, said Assignor has sold, assigned, transferred and set over, and by these presents does sell, assign, transfer and set over, unto the Assignee, its successors, legal representatives and assigns, its entire right, title and interest in and to the above-mentioned inventions, applications for Letters Patent, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations, and continuations-in-part of said patents or applications, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by said Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignor, had this sale and assignment not been made.

AND for the same consideration, said Assignor hereby covenants and agrees to and with said Assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and that said Assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, the said Assignor hereby covenants and agrees to and with said Assignee, its successors, legal representatives and assigns, that said Assignor will, whenever counsel of said Assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said invention, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said invention in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said invention, without charge to said Assignee, its successors, legal representatives and assigns, but at the cost and expense of said assignee, its successors, legal representatives and assigns.

AND said Assignor hereby requests the Commissioner of Patents to issue said Letters Patent of the United States to Teikoku Pharma USA, Inc. as the assignee of said inventions and the Letters Patent to be issued thereon for the use and behalf of Teikoku Pharma USA, Inc., its successors, legal representatives and assigns.

Date 06/07/11

Assignor:

Mr. Junji Kachi, Chief Executive Officer

Travanti Pharma Inc.

APPENDIX A

COUNTRY	REFERENCE#	FILED	SERIAL#	ISSUED	PATENT#
UNITED STATES	TRAV-006	1/23/2004	10/763,628	1/11/2011	7,867,511
EUROPEAN PAT.	TRAV-006EP	1/20/2005	05711945.5		
JAPAN	TRAV-006JP	1/20/2005	2006-551380	12/10/2010	4642784
JAPAN	TRAV-006JPDIV	1/20/2005	2010-156607		
WIPO	TRAV-006WO	1/20/2005	US2005/002246		
UNITED STATES	TRAV-006CIP	3/26/2009	12/412,144		
UNITED STATES	TRAV-006DIV	11/19/2009	12/621,619		
WIPO	TRAV-006WO2	2/25/2010	US2010/000552		
UNITED STATES	TRAV-006CON	11/23/2010)12/952,516		
UNITED STATES	TRAV-006CON2	12/22/2010)12/976,610		

PATENT REEL: 026435 FRAME: 0497

RECORDED: 06/13/2011